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Darunavir is an efﬁcacious drug; however, pharmacokinetic variability has been reported. The objective of this study was to ﬁnd
predisposing factors for low darunavir plasma concentrations in patients starting the once- or twice-daily dosage. Darunavir
plasma concentrations from January 2010 till December 2014 of human immunodeﬁciency virus-infected individuals treated in
the outpatient clinic of the University Medical Center Groningen were retrospectively reviewed. The ﬁrst darunavir plasma con-
centration of patients within 8 weeks after initiation of darunavir therapy was selected. A dichotomous logistic regression analysis
was conducted to select the set of variables best predicting a darunavir concentration belowmedian population pharmacokinetic
curve. In total 113 patients were included. The variables best predicting a darunavir concentration besides food intake included
age together with estimated glomerular ﬁltration rate (Hosmer–Lemeshow test P = 0.945, Nagelkerke R2 = 0.284). Systematic
evaluation of therapeutic drug monitoring results may help to identify patients at risk for low drug exposure.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Darunavir exposure is improved by concomitant food intake.
• Darunavir has a high pharmacokinetic variability.
• Factors such as demographics, concomitant medication and polymorphisms of cytochrome P450 3A4 isoenzymes are de-
scribed as potential contributors to pharmacokinetic variability.
WHAT THIS STUDY ADDS
• Age and estimated glomerular ﬁltration rate are predictors of a darunavir plasma concentration belowmedian population
pharmacokinetic curve.
• The combination of tenofovir and darunavir potentially leads to decreased estimated glomerular ﬁltration rate and in-
creased darunavir exposure and merits further investigation.
• Systematic evaluation of therapeutic drug monitoring results may help to identify risk factors for low drug exposure.
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Introduction
Darunavir (DRV) is a human immunodeﬁciency virus (HIV)
protease inhibitor (PI) that is used for the treatment of
HIV-1 infection in antiretroviral treatment-naïve and
treatment-experienced adults and paediatric patients aged
≥6 years [1]. Once-daily DRV 800 mg is approved for use in
treatment-naïve patients and the twice daily dosage of
DRV 600 mg is approved for use in treatment-experienced
adults with DRV resistance-associated mutations [2]. As
DRV is extensively metabolized by cytochrome P450
3A4 and being a substrate of P-glycoprotein as well, it
is coadministered with ritonavir (RTV) 100 mg or
cobicistat 150 mg to increase its exposure [1, 3–5]. Further-
more, concomitant food intake is advised to improve DRV
bioavailability [6].
DRV is considered a safe and efﬁcacious drug; however,
substantial pharmacokinetic variability has been reported
[1, 7]. Factors such as demographics, treatment adherence,
concomitant medication and polymorphisms of cyto-
chrome P450 3A4 isoenzymes contribute to the observed
variability [1, 5, 7]. Pharmacokinetic variability can poten-
tially result in suboptimal DRV plasma concentrations.
Suboptimal DRV plasma concentrations are highly undesir-
able as they can lead to drug resistance, insufﬁcient virologi-
cal response or a virological breakthrough in patients who
earlier had an undetectable viral load [8]. Therapeutic drug
monitoring is therefore routinely performed to assure
adequate drug exposure [8].
Despite the relatively long use and experience with DRV
in daily practice, little is documented concerning the
potential risk factors for a relatively low DRV concentration
in HIV-infected individuals in an outpatient setting. The
aim of the present study was to investigate the frequency as
well as predisposing factors associated with DRV plasma
concentration below the median population pharmacoki-
netic curve in an outpatient setting.
Methods
Study design and participants
We performed a retrospective study on demographics,
measured DRV plasma concentrations and patient character-
istics in HIV patients treated with DRV in the University
Medical Center Groningen (UMCG), The Netherlands. All
patients aged ≥18 years and using DRV were eligible for
inclusion in this study. A database was created by extracting
all measured DRV plasma concentrations from January 2010
to December 2014 from the UMCG electronic patient
database. Due to intrapatient variability and potential dose
adjustments, we considered only the ﬁrst DRV level of each
patient within 8 weeks after initiation of the DRV therapy
for inclusion. DRV plasma concentrations were excluded if
the time of ingestion relative to the collection of the blood
sample was unknown. The ethical review board of the UMCG
evaluated the study protocol and waived the need for written
informed consent due to the retrospective nature of the study
(METc 2015.010).
Data collection and management
The following data were extracted from the medical records
of the participants and included in the research database:
sex, age, weight (during visit of drug level measurement),
height, drug abuse, documented adherence, comorbidity,
serum creatinine concentration, aspartate aminotransferase,
alanine aminotransferase, CD4+ cell count and viral load.
The medical records of all participants were studied for
medication potentially inﬂuencing the DRV concentrations.
When the possibility of nonadherence was suggested in
the medical record, the patient was classiﬁed as potentially
nonadherent. Data concerning drug abuse included alcohol
abuse (persistent use of ≥14 units of alcohol weekly) [9] and
the use of recreational drugs. Comorbidities with a known
effect on pharmacokinetics were included in the database
(e.g. renal, hepatic, and/or gastrointestinal morbidity). The
estimated glomerular ﬁltration rate (eGFR) was calculated
using the Chronic Kidney Disease Epidemiology collabora-
tion (CKD-EPI) formula [10]. The laboratory results (i.e. creat-
inine, aspartate aminotransferase, alanine aminotransferase,
CD4+ cell count and viral load) included in the database
corresponded with the date of the DRV plasma concentration
or within a period of ±3 months. The De Ritis ratio [11] was
calculated to interpret the hepatic function.
Bioanalytical procedure and pharmacokinetic
analyses
The concentrations of DRV in human plasma were analysed
in the Laboratory of the Department of Clinical Pharmacy
and Pharmacology at the UMCG by a validated liquid
chromatography–tandem mass spectrometry procedure. All
analyses were performed on a Finnigan TSQ Quantum
Discovery (San Jose, CA, USA) triple quadrupole liquid
chromatography–tandemmass spectrometer with a Finnigan
Surveyor LC pump and a Finnigan Surveyor autosampler. The
calibration curves were linear within the concentration range
of 0.335 to 33.5 mg l–1 for DRV and had a correlation coefﬁ-
cient (R2) of 0.999. The lower limit of quantiﬁcation for
DRV was 0.27 mg l–1. This method was precise and accurate
as within-day precision ranged between 2.2 and 3.2% for
DRV, and between-day precision ranged from 3.0 to 5.2%.
The calculated accuracy ranged from 0.0% to 11.8%.
Performance of the assay was within accepted limits of
acceptance (accuracy and precision <10%) in our laboratory
as conﬁrmed by participation in the international proﬁciency
testing program [12].
To estimate time-adjusted DRV plasma concentrations, a
DRV-iterative two-stage Bayesian population pharmacoki-
netic model with the software package MWPharm 3.82
(Mediware, Groningen, The Netherlands) was used [13]. The
model for DRV was a one-compartment model with input
and elimination from the central compartment. Parameters
for this model are: a volume of distribution of the
central compartment of 2 l kg–1 [standard deviation (s.d.)
0.5 l kg–1], a total body clearance of 6.3 l h–1 1.85m–2 (s.d.
1.57 l h–1 1.85m–2), ﬁrst order absorption constant of 1 h–1
(s.d. 0.25 h–1) and a bioavailability of 0.8 (in combination
with RTV). This model was built in-house and derived from
data provided in the literature [14]. Similar to standard care,
each time-adjusted DRV plasma concentration was compared
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with a median population pharmacokinetic curve for the
once-daily or twice-daily dosage of DRV [15]. Consistent with
daily practice the DRV plasma concentrations were dichoto-
mized as either above or below the median curve. The median
curves do not represent the minimal effective concentration,
but are used in standard care as cut-off values for follow-up
[15]. A DRV trough concentration below 1.07 mg l–1 for the
once-daily dosage and 2.60 mg l–1 for the twice daily dosage
is an indication for follow-up. This follow-up consists of
repeated plasma drug concentration measurement, addi-
tional food intake advice and additional questions and
guidance concerning therapy adherence.
Statistical analysis
Age, body mass index, eGFR, De Ritis ratio, comorbidity, drug
abuse and documented adherence were tested for association
with DRV plasma concentration above or below median
population pharmacokinetic curve. We conducted a di-
chotomous logistic regression analysis with manual back-
ward selection based on P-values to identify which set of
variables best predicted a DRV plasma concentration below
the median population pharmacokinetic curve. Comorbidity,
recreational drug abuse and documented adherence were
marked as categorical covariates. We assessed the variance
of the model using Nagelkerke R2 and determined the
goodness-of-ﬁt by Hosmer–Lemeshow. Variables were
checked for linearity and included as dummy variables
(indicator variables) if necessary. All statistical analyses were
performed using SPSS for Windows, version 22.0 (IBM SPSS,
Chicago, Illinois).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharmacol-
ogy.org, the common portal for data from the IUPHAR/BPS
Guide to PHARMACOLOGY [16], and are permanently
archived in the Concise Guide to PHARMACOLOGY
2015/16 [17].
Results
In total, 113 initial DRV plasma concentrations from 113 pa-
tients were measured within 8 weeks after initiation of DRV
therapy and were therefore included in the research database.
Ninety-four participants were using DRV/RTV 800/100 mg
once-daily and 19 participants were using DRV/RTV
600/100 mg twice-daily. All participants were using RTV as a
booster. Eighty-eight (78%) participants were among others
using tenofovir simultaneously with DRV and seven (6%)
participants were using raltegravir simultaneously with
DRV. No other concomitant use of nonantiretroviral medica-
tion interacting with DRV was found after assessing the med-
ical records of the participants. Further demographic
characteristics are presented in Table 1.
The median (interquartile range) DRV plasma concentra-
tion was 2.8 (1.8–4.2) mg l–1 and 31 (27.4%) DRV plasma con-
centrations were classiﬁed below the median population
pharmacokinetic curve. In Table 2, the patient characteristics
and DRV drug concentrations below or above median
population pharmacokinetic curve values are shown. Due to
a lack of linearity with the dependant variable the variables
age, eGFR and body mass index were included in the logistic
regression as dummy variables divided into four quartiles.
The model best predicting a DRV level below the median
population pharmacokinetic curve included the variables
age and eGFR (Hosmer–Lemeshow goodness-of-ﬁt test
P = 0.945, Nagelkerke R2 = 0.284). The results of the dichoto-
mous logistic regression are presented in Table 3.
Discussion
In this descriptive study we assessed the predictive value of
patient- and disease-related factors on DRV plasma concen-
trations after initiation of the DRV therapy. In a dichotomous
logistic regression analysis, we found that the combination of
age and eGFR were associated with a DRV plasma concentra-
tion below the median population pharmacokinetic curve.
Like other antiretroviral PIs, DRV pharmacokinetics are
characterized by large interpatient variability [1, 7]. The ob-
served variability could partly be caused by inadequate food
intake as DRV is advised to be taken concomitantly with food
to achieve adequate exposure [6]. To identify other potential
contributors to a DRV plasma concentration below the me-
dian population pharmacokinetic curve, besides food intake,
in this study we focused on several patient- and disease-
related factors. More than a quarter (27.4%) of the DRV
plasma concentrations were below the median curve trigger-
ing physicians to change their follow-up strategy. Theoreti-
cally it would be expected that 50% of the DRV plasma
concentrations would be below the median curve. The me-
dian population pharmacokinetic curves used do not have a
relation with therapeutic effectiveness of DRV, but provide a
cut-off value in standard care to determine whether follow-
up is prudent [15, 18]. Follow-up consists of an additional food
intake advice, additional questions and guidance concerning
therapy adherence and a repeated blood sample for DRV
monitoring. Therefore, in daily practice physicians are aiming
for higher then median DRV plasma concentrations.
That eGFR is found to be a predictor for below median
DRV plasma concentration in combination with age in the
current study is a remarkable ﬁnding, since DRV is mainly
eliminated by the liver. A higher than average eGFR alone
would therefore presumably have a minor impact on DRV
plasma concentration in daily practice. The observed inverse
relation between eGFR and DRV concentrations in the
current study might potentially be induced by the concomi-
tant use of tenofovir. During the study period, 78% of the
participants were using tenofovir simultaneously with DRV.
A higher risk of renal impairment has been reported in
patients receiving tenofovir and a RTV boosted PI, such as
DRV [19]. In addition, the summary of product characteristics
of DRV demonstrates that coadministration of tenofovir
(300 mg once daily) and DRV/RTV (300/100 mg twice daily)
increased DRV AUC, Cmax and Cmin by 21%, 16% and 24%,
respectively [20]. The observed inverse relationship between
eGFR and DRV concentration might be due to concomitant
tenofovir usage, which is nephrotoxic on the one hand and
inhibits DRV clearance on the other [19, 20]. Earlier studies
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Table 1
Demographic characteristics of the 113 study participants at time of sampling
Characteristics Value
Number of participants 113 (89 male)
Mean age (years) 43 (20–67)
Median BMI (kg m–2), IQR 23.50 (21.1–26.0)
BMI subgroups, n (%)
< 18 kg m–2 5 (4.4%)
18–25 kg m–2 64 (56.6%)
> 25 kg m–2 34 (30%)
Missinga 10 (9%)
eGFR (ml min 1.73 m–2), mean (SD) 103.3 (23.3)
Median AST (IQR) 29 (23–35)
Median ALT (IQR) 25 (17.5–33.5)
Median CD4+ cell count (IQR) 430 (285–605)
Undetectable viral load in 55 patients
Median Viral load in patients with detectable load (n = 58), copies ml–1 (IQR) 600 (242–1486)
Documented comorbidity
Number of patients with hepatic morbidity 6
Number of patients with gastrointestinal morbidity 4




Documented potentially nonadherent 9
aBody mass index (BMI) of these individuals could not be calculated as only body weight was recorded. IQR, interquartile range; SD, standard de-
viation; eGFR, estimated glomerular ﬁltration rate; AST, aspartate aminotransferase, ALT, alanine aminotransferase
Table 2
Patient characteristics and darunavir plasma concentrations below or above median population pharmacokinetic curve values
Variable Below population median (n = 31) Above population median (n = 82) P-value
Age mean (years) 41 44 0.138 (t test)
Sex (male), n (%) 21 (68%) 68 (83%) 0.078 (Pearson χ2)
BMI (median, IQR) 24.3 (21.3–27.5) 23.2 (20.8–25.7) 0.298 (MWU)
eGFR, mean (SD) 114.5 (16.9) 99.0 (24.1) <0.001, t test
Earlier documented nonadherence, n (%) 5 (16.1%) 4 (4.9%) 0.062 (Fisher exact)
Detectable HIV viral load, n (%) 17 (54.8%) 41 (50%) 0.65 (Pearson χ2)
Recreational drugs/alcohol abuse 8 (26.8%) 17 (20.7%) 0.56 (Pearson χ2)
De Ritis, median (IQR) 1.3 (0.9–1.6) 1.1 (0.9–1.5) 0.33 (MWU)
MWU, Mann–Whitney U test; BMI, body mass index; IQR, interquartile range; SD, standard deviation; eGFR, estimated glomerular ﬁltration rate;
HIV, human immunodeﬁciency virus.
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suggested that raltegravir also could lower DRV concentra-
tions [21, 22]. Of the seven participants using raltegravir
and DRV simultaneously in the current study, two had a
DRV concentration below median curve. Unfortunately, due
to the unequally divided and small sample sizes of both
tenofovir and raltegravir users and nonusers a subanalysis
was not possible.
The other variable in the prediction model was age. The
highest quartile of the variable age (>53 years) showed lower
risk of a DRV plasma concentration below median curve in
combination with eGFR. The effect of age on plasma antire-
troviral drug (PI) exposure was shown earlier [23]. The plasma
concentrations of DRV might be higher with increasing age
due to a lowered hepatic (CYP450 3A4 enzyme) activity in
older people [24, 25].
An important limitation in the current study is that no data
concerning concomitant food intake with DRV ingestion were
available. The observed variability in DRV concentrations in
the current study might potentially be confounded by inade-
quate concomitant food intake, although that is unlikely based
on a prior study assessing food intake concomitantly with DRV
[26]. Another weakness is the limited number of events in the
model. Nevertheless, the results of this study provide an in-
sight into the DRV plasma concentrations after start of therapy
at an HIV outpatient clinic.
Linking several patient- and disease-related factors to the
routinely measured DRV plasma concentrations shows that
younger patients with a higher than average eGFR more
frequently have a DRV plasma concentration below median
curve. The impact of tenofovir has to be clariﬁed in future
studies in populations with a larger proportion of tenofovir-
free regimens to facilitate interpretation. Although therapeu-
tic drug monitoring is not a substitute for clinical judgement,
it can be a powerful tool for identifying patients with
lower DRV concentrations and subsequently at risk for drug
resistance.
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